| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:label
| |
| rdfs:subClassOf
| |
| Concept_In_Subset
| |
| Semantic_Type
| - Inorganic Chemical
- Pharmacologic Substance
|
| Preferred_Name
| |
| NSC_Code
| |
| UMLS_CUI
| |
| CAS_Registry
| |
| Accepted_Therapeutic_Use_For
| - Osteogenic sarcoma; CNS and germ cell tumors; ovarian; lung; head and neck; endometrial; esophageal; bladder; breast; cervical cancer.
|
| In_Clinical_Trial_For
| - Lymphoma; Neuroblastoma; Non-small cell lung cancer; Oropharyngeal cancer; Osteosarcoma; Peritoneal cavity cancer
- Bladder cancer; Brain tumor; Breast cancer; CNS cancer; Colon cancer; Esophageal cancer; Fallopian Tube cancer; Gastrointestinal cancer; Germ cell tumor; Glioma; Intraocular retinoblastoma; Kidney cancer; Liver cancer; Urethral cancer; Ovarian cancer
- Prostate cancer; Rhabdomyosarcoma; Renal cell cancer; Salivary Gland cancer; Small cell lung cancer; Soft tissue sarcoma; Thymoma; Wilms tumor
|
| FDA_UNII_Code
| |
| Contributing_Source
| |
| ALT_DEFINITION
| - A drug that is used to treat advanced ovarian cancer that has never been treated or symptoms of ovarian cancer that has come back after treatment with other anticancer drugs. It is also used with other drugs to treat advanced, metastatic, or recurrent non-small cell lung cancer and is being studied in the treatment of other types of cancer. Paraplatin is a form of the anticancer drug cisplatin and causes fewer side effects in patients. It attaches to DNA in cells and may kill cancer cells. It is a type of platinum compound.NCI-GLOSS
|
| PDQ_Open_Trial_Search_ID
| |
| PDQ_Closed_Trial_Search_ID
| |
| Chemical_Formula
| |
| Legacy_Concept_Name
| |
| CHEBI_ID
| |
| FULL_SYN
| - ParaplatineFBNCI
- CarboplatinPTNCI
- ParaplatinPTNCI-GLOSSCDR0000635889
- CBDCASYDTPNSC0241240
- CarboplatinoSYNCI
- platinum, diammine(1,1-cyclobutanedicarboxylato(2-))-, (SP-4-2)SNNCI
- NovoplatinumFBNCI
- Paraplatin AQFBNCI
- carboplatinPTNCI-GLOSSCDR0000045182
- (SP-4-2)-diammine[1,1-cyclobutanedicarboxylato(2--)-O,O']platinumSNNCI
- cis-diammine(1,1-cyclobutanedicarboxylato) platinum(II)SNNCI
- JM-8CNNCI
- CBDCAABNCI
- ErcarFBNCI
- Carboplatin HexalSYNCI
- 1,1-cyclobutanedicarboxylic acid platinum complexSNNCI
- cis-diammine(cyclobutanedicarboxylato)platinum IISNNCI
- CarbotecFBNCI
- CarbosinFBNCI
- DisplataFBNCI
- CarbosolFBNCI
- NealorinFBNCI
- ParaplatBRNCI
- CARBOPLATINPTFDABG3F62OND5
- RibocarboFBNCI
- CarboplatFBNCI
- PlatinwasFBNCI
- Cis-Diammine(cyclobutane-1,1-dicarboxylato)platinumSNNCI
- BlastocarbFBNCI
- ParaplatinBRNCI
|
| DEFINITION
| - A second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. This agent possesses tumoricidal activity similar to that of its parent compound, cisplatin, but is more stable and less toxic. (NCI04)NCI
|
| code
| |
| sameAs
| |
| http://linked.open...y/mesh/hasConcept
| |
| is someValuesFrom
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)